Beam Therapeutics Inc (BEAM)
22.78
-0.35
(-1.51%)
USD |
NASDAQ |
May 06, 16:00
22.84
+0.06
(+0.26%)
Pre-Market: 08:03
Beam Therapeutics Cash from Operations (TTM): -149.20M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -149.20M |
September 30, 2023 | -353.46M |
June 30, 2023 | -338.17M |
March 31, 2023 | -305.78M |
December 31, 2022 | 22.53M |
September 30, 2022 | 93.55M |
June 30, 2022 | 171.05M |
March 31, 2022 | 190.80M |
December 31, 2021 | -66.27M |
Date | Value |
---|---|
September 30, 2021 | -92.40M |
June 30, 2021 | -116.62M |
March 31, 2021 | -106.93M |
December 31, 2020 | -95.74M |
September 30, 2020 | -89.24M |
June 30, 2020 | -85.02M |
March 31, 2020 | -73.54M |
December 31, 2019 | -72.00M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-353.46M
Minimum
Sep 2023
190.80M
Maximum
Mar 2022
-86.26M
Average
-89.24M
Median
Sep 2020
Cash from Operations (TTM) Benchmarks
Eli Lilly and Co | 3.676B |
Moderna Inc | -2.882B |
Editas Medicine Inc | -132.18M |
Intellia Therapeutics Inc | -394.09M |
Perspective Therapeutics Inc | -36.91M |